MAPT and supranuclear palsy, progressive, 1: Further research is warranted to determine if distinct clinical presentations, disease progression dynamics and neuropathologies within a single disease entity [e.g. progressive supranuclear palsy (PSP)] can be explained by finer variations of the main tau strain or are determined by other factors, such as genetic, epigenetic or environmental influences.